Intensity-modulated Radiation Therapy Combined With Cisplatin or Nedaplatin Chemotherapy in Nasopharyngeal Carcinoma
This phase II trial is studying cisplatin or nedaplatin combine with IMRT to evaluate which one is better efficacy and security in nasopharyngeal carcinoma.
Nasopharyngeal Carcinoma
DRUG: Cisplatin|DRUG: Nedaplatin
locoregionally control rate, 3 months after treatment, 3 months
Survival, 1 year Progress Free Survival,Disease Free Survival,3 years and 5 years Over All Survival,Safety, 1,3,5 years
This phase II trial is studying cisplatin or nedaplatin combine with IMRT to evaluate which one is better efficacy and security in nasopharyngeal carcinoma.